NanoCarrier Presents Favorable Data from Phase IIa Portion of NC-6004 Phase II Clinical Study in Combination with Keytruda
October 25, 2020 at 09:00 pm EDT
Share
NanoCarrier announced that on October 24 to 25, at the 32nd EORTC-NCI-AACR Symposium, the company presented favorable results of the NC-6004 Phase IIa clinical study for head and neck cancer in combination therapy of NC-6004 plus Keytruda, an immune checkpoint inhibitor. The maximum tolerated dose (MTD) of NC-6004 was not identified and the recommended dose (RD) of NC-6004 was concluded to be 135 mg/m2. Partial response (PR) was seen in 4 patients. The overall response rate (ORR) was 25% and the disease control rate was 87.5%. The median progression-free survival (mPFS) was 4.0 months for the overall population, and 5.2 months for 6 patients receiving 135 mg/m2 of NC-6004 which is the RD in Phase IIb. The safety profile was favorable and dose limiting toxicity (DLT) was not observed. One patient (6.3%) experienced serious adverse events. This clinical study showed more favorable efficacy compared with the Keynote-040 Phase III clinical study of pembrolizumab (Keytruda), where the overall response rate was 14.6% and the mPFS was 2.1 months. Based on these positive results for the Phase IIa part, NanoCarrier has great expectations for results in Phase IIb, in which NC-6004 plus Keytruda is compared with Keytruda alone. The company are proceeding with preparations for the Phase IIb clinical study, and expecting patient recruitment within this year.
Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.